The Breast
Volume 19, Issue 6 , Pages 499-505 , December 2010

Trends in incidence of ductal carcinoma in situ: The effect of a population-based screening programme

  • Ragnhild Sørum

      Affiliations

    • Cancer Registry of Norway, Department of Screening-based Research, Box 5313 Majorstuen, N-0304 Oslo, Norway
    • Corresponding Author InformationCorresponding author. Tel.: +47 22 45 13 00; fax: +47 22 45 13 70.
    • ,
  • Solveig Hofvind

      Affiliations

    • Cancer Registry of Norway, Department of Screening-based Research, Box 5313 Majorstuen, N-0304 Oslo, Norway
    • Oslo University College, Faculty of Health Sciences, Oslo, Norway
    • ,
  • Per Skaane

      Affiliations

    • Oslo University Hospital Ullevaal, Department of Radiology, University of Oslo, Oslo, Norway
    • ,
  • Tor Haldorsen

      Affiliations

    • Cancer Registry of Norway, Department of Screening-based Research, Box 5313 Majorstuen, N-0304 Oslo, Norway

Received 7 April 2010 ,Revised 21 May 2010 ,Accepted 21 May 2010.

References 

  1. Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996;275(12):913–918
  2. Levi F, Te VC, Randimbison L, La Vecchia C. Trends of in situ carcinoma of the breast in Vaud, Switzerland. Eur J Cancer. 1997;33(6):903–906
  3. Luke C, Priest K, Roder D. Changes in incidence of in situ and invasive breast cancer by histology type following mammography screening. Asian Pac J Cancer Prev. 2006;7(1):69–74
  4. van Steenbergen LN, Voogd AC, Roukema JA, Louwman WJ, Duijm LE, Coebergh JW, et al. Screening caused rising incidence rates of ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2009;115(1):181–183
  5. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102(3):170–178
  6. Barchielli A, Federico M, De LV, Bucchi L, Ferretti S, Paci E, et al. In situ breast cancer: incidence trend and organised screening programmes in Italy. Eur J Cancer. 2005;41(7):1045–1050
  7. Smart CR, Myers MH, Gloeckler LA. Implications from SEER data on breast cancer management. Cancer. 1978;41(3):787–789
  8. Hofvind S, Vacek PM, Skelly J, Weaver DL, Geller BM. Comparing screening mammography for early breast cancer detection in Vermont and Norway. J Natl Cancer Inst. 2008;100(15):1082–1091
  9. Simon MS, Lemanne D, Schwartz AG, Martino S, Swanson GM. Recent trends in the incidence of in situ and invasive breast cancer in the Detroit metropolitan area (1975–1988). Cancer. 1993;71(3):769–774
  10. Ernster VL, Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr. 1997;22:151–156
  11. Zheng T, Holford TR, Chen Y, Jones BA, Flannery J, Boyle P. Time trend of female breast carcinoma in situ by race and histology in Connecticut, USA. Eur J Cancer. 1997;33(1):96–100
  12. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94(20):1546–1554
  13. Erbas B, Amos A, Fletcher A, Kavanagh AM, Gertig DM. Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: should older women continue screening?. Cancer Epidemiol Biomarkers Prev. 2004;13(10):1569–1573
  14. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350(14):1430–1441
  15. Evans AJ, Pinder SE, Ellis IO, Wilson AR. Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease?. J Med Screen. 2001;8(3):149–151
  16. Jones JL. Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective. Breast Cancer Res. 2006;8(2):204
  17. Lagios MD. Heterogeneity of duct carcinoma in situ (DCIS): relationship of grade and subtype analysis to local recurrence and risk of invasive transformation. Cancer Lett. 1995;90(1):97–102
  18. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96(6):443–448
  19. Hofvind S, Geller B, Vacek PM, Thoresen S, Skaane P. Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program. Eur J Epidemiol. 2007;22(7):447–455
  20. Larsen IK, Smastuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–1231
  21. Statistical methods in cancer research. The design and analysis of cohort studies. vol. 2. Lyon: International Agency for Research on Cancer; 1987;pp. 54
  22. Tan PH. Pathology of ductal carcinoma in situ of the breast: a heterogeneous entity in need of greater understanding. Ann Acad Med Singap. 2001;30(6):671–676
  23. Perry N, Broeders M, De Wolf C, Tornberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. 4th ed.. Belgium: European Communities; 2006;
  24. Widmark A, Olsen JB. Mammografivirksomhet i Norge: Tekniske resultater. [Strålevern Rapport 1995:5]. Norwegian Radiation Protection Authority [In Norwegian].
  25. Stockton D, Davies T, Day N, McCann J. Retrospective study of reasons for improved survival in patients with breast cancer in east Anglia: earlier diagnosis or better treatment. BMJ. 1997;314(7079):472–475
  26. Kuhl CK, Schrading S, Bieling HB, Wardelmann E, Leutner CC, Koenig R, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet. 2007;370(9586):485–492
  27. Skaane P. Studies comparing screen-film mammography and full-field digital mammography in breast cancer screening: updated review. Acta Radiol. 2009;50(1):3–14
  28. Reeves GK, Beral V, Green J, Gathani T, Bull D. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol. 2006;7(11):910–918
  29. Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V. Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. J Natl Cancer Inst. 1997;89(1):76–82
  30. Warnberg F, Nordgren H, Bergh J, Holmberg L. Ductal carcinoma in situ of the breast from a population-defined cohort: an evaluation of new histopathological classification systems. Eur J Cancer. 1999;35(5):714–720
  31. Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, et al. Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications. European Commission Working Group on Breast Screening Pathology. Hum Pathol. 1998;29(10):1056–1062
  32. Cutuli B, Lemanski C, Fourquet A, de Lafontan B, Giard S, Meunier A, et al. Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience. Br J Cancer. 2009;100(7):1048–1054
  33. Evans WP, Starr AL, Bennos ES. Comparison of the relative incidence of impalpable invasive breast carcinoma and ductal carcinoma in situ in cancers detected in patients older and younger than 50 years of age. Radiology. 1997;204(2):489–491

PII: S0960-9776(10)00146-3

doi: 10.1016/j.breast.2010.05.014

The Breast
Volume 19, Issue 6 , Pages 499-505 , December 2010

Article Tools

* Image Usage & Resolution